Overview

A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies

Status:
Unknown status

Trial end date:
2020-03-01

Target enrollment:

Participant gender:

Summary

This study a nonrandomized, open-label, uncontrolled, single group assignment, safety and activity study in subjects with histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.

Phase:

Phase 1

Details

Lead Sponsor:

Athenex, Inc.
Kinex Pharmaceuticals Inc

Treatments:

Irinotecan